Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ovarian Cancer Recurrent × Lenalidomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 45 Lymphoma, Large B-Cell, Diffuse 20 Lymphoma, Follicular 19 Lymphoma 14 Leukemia, Lymphocytic, Chronic, B-Cell 14 Recurrence 12 Lymphoma, B-Cell, Marginal Zone 10 Lymphoma, Non-Hodgkin 9 Lymphoma, Mantle-Cell 9 Lymphoma, B-Cell 9 Neoplasms, Plasma Cell 6 Waldenstrom Macroglobulinemia 5 Leukemia, Myeloid, Acute 5 Neoplasms 4 Burkitt Lymphoma 4 Prostatic Neoplasms 3 Myelodysplastic Syndromes 3 Lymphoma, T-Cell, Peripheral 3 Lymphoma, T-Cell 3 Leukemia 3 Hodgkin Disease 3 Hematologic Neoplasms 3 Sezary Syndrome 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Mycosis Fungoides 2 Lymphoma, Large-Cell, Immunoblastic 2 Lymphoma, Large-Cell, Anaplastic 2 Leukemia, Myelomonocytic, Chronic 2 Intraocular Lymphoma 2

Interventions

poly(I).poly(c12,U) 1 pembrolizumab 1 Paclitaxel 1 Lenalidomide 1 Interferon alpha-2 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01111903 2016-03-17

REV

ARCAGY/ GINECO GROUP

Phase 1/2 Completed

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡